Indian scientist couple at Deakin University bring ray of hope to prostate cancer patients

In a major scientific research breakthrough, the Indian husband-wife, both scientists, have found out that a protein in cow and human milk, coupled with Doxorubicin can successfully treat prostate cancer, negates toxic side effects in prostrate cancer research

Dr Rupinder Kanwar and her husband Professor Jagat Kanwar in their Laboratory at Deakin University.

New Delhi: A medical scientists’ team, at Deakin University, Australia, has recently announced that they achieved a breakthrough in prostate cancer treatment. Dr Rupinder Kanwar and her husband Professor Jagat Kanwar, along with two others, revealed that by piggy backing a chemotherapy drug onto a well-known milk protein could create a combination that is lethal for cancer cells without the toxic side-effects.

When coupled with the milk protein lactoferrin, the Dox can be delivered directly into the nucleus of prostate cancer cells and will kill the cells as well as drug resistant cancer stem cells, without any side-effects. This has been published in the prestigious international journal, Nature. (Read the detailed article here)

According Dr Rupinder Kanwar, a senior research fellow with the Deakin Medical School’s Centre for Molecular and Medical Research, doctors had stopped using Dox to treat prostate cancer because of the side-effects. She said, “Dox is used widely for treating several types of cancers and known for causing toxicity to heart, brain, kidneys and leading to cardiac arrest/heart failure.”

Dr Rupinder points towards the fact that the prostate cancer is one of the few cancers where chemotherapy is not the primary treatment. This is because these particular cancer cells are able to flush out the drug and become resistant to it, while the administered Dox continues to kill off the body’s normal cells resulting in a range of side effects, the most damaging of which is heart failure, she says.

“With this latest study we have shown that by coupling Dox with lactoferrin the cancer cells take in the drug rather than pump it straight out,” Dr Rupinder added.

Lactoferrin is an iron-binding protein found in cow milk and human milk. It is known for its immune boosting and antimicrobial properties making it an important part of the body’s protection against infection. It is also added as a key ingredient in baby formula. It is lactoferrin’s ability as an iron transporting protein to mop up much needed iron for growth of microbes (bacteria and parasites) from the site of infection and its cancer cell killing activities that are exploited by the Deakin scientists to create an anticancer bio-drug that has no side-effects and improves the immune system.

Previous work by the team with other types of cancer, funded by the AustraliaIndia Strategic Research Fund (AISRF) to Prof Jagat Kanwar and Dr Rupinder Kanwar, found that lactoferrin is not digested by the gut enzymes when fully saturated with iron and given as smart nano-capsules.

Prof Jagat Kanwar said, “This latest study builds on this previous work, whereby to target toxicity and drug resistance, we coupled the Dox with lactoferrin which was then fed to a particular breed of mice that naturally develop prostate cancer. Rather than being pumped out by the cancer cells, Dox was taken to these cells by lactoferrin through its receptors which then stays in the nucleus of the cancer cells to perform its lethal action.”

He added, “Within 96 hours all the cancer cells were dead when grown in 3D cancers in a culture dish from drug resistant and cancer stem cells. In feeding experiments, as an added benefit, there was an increase in red blood cells, white blood cells and haemoglobin indicating that the immune system had also been boosted. Interestingly, this combination not only targeted the prostate tumour development in mice, it also led to repair of the Dox induced damage to vital organs including heart and brain.”

The main goal of the research team now is to move to trials with real patients. “The results of our research to date show great promise that we could soon develop personalised medication for prostate cancer patients,” Dr Rupinder said.